American Diabetes Association

Table 2

MACE according to severe hypoglycemia and treatment group

Patient population	Liraglutide		Placebo			HR (95% CI)	P-interaction
Patient population	n	MACE*	n		MACE*	HR (95% CI)	P-interaction
All	4,668	608	4,672	694		0.87 (0.78, 0.97)
With severe hypoglycemia	114	26	153	40		0.85 (0.52, 1.39)	0.90
Without severe hypoglycemia	4,554	582	4,519	654		0.88 (0.78, 0.98)

Patient population	Liraglutide		Placebo			HR (95% CI)	P-interaction
Patient population	n	MACE*	n		MACE*	HR (95% CI)	P-interaction
All	4,668	608	4,672	694		0.87 (0.78, 0.97)
With severe hypoglycemia	114	26	153	40		0.85 (0.52, 1.39)	0.90
Without severe hypoglycemia	4,554	582	4,519	654		0.88 (0.78, 0.98)

HRs were estimated with the use of a Cox proportional hazards model with treatment as a covariate.

*First MACE (CV death, nonfatal myocardial infarction, or nonfatal stroke).